EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY

Geert R. D'Haens  ¹     Marla C. Dubinsky  ²     Peter Irving  ³     Xingyuan Li  ⁴     Stefanie Howaldt  ⁵     Juris Pokrotnieks  ⁶     Kathryn Krueger  ⁶     Janelle Laskowski  ⁶     Trevor Lissoos  ⁶     Joe Milata  ^6    
1 Amsterdam University Medical Centers, Amsterdam, Netherlands
² Icahn School of Medicine at Mount Sinai, New York City, United States
³ Guy´s and St Thomas´ Hospital, London, United Kingdom
⁴ Eli Lilly and Company, Indianapolis, United States
⁵ Research Institute for IBD-HaFCED e.K., Hamburg, Germany
⁶ Riga Stradins University, Riga, Latvia

Topic
IBD, Nurses, Primary Care

Session
Clinical trials in ulcerative colitis II

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)